Immix Biopharma, Inc.(IMMX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
IMMX Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Immix Biopharma, Inc. (IMMX), a Healthcare sector company. IMMX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Immix Biopharma, Inc. reports net income of $-11.6M, free cash flow of $-11.8M. Top institutional holders of IMMX by reported 13-F value include Jupiter Topco, Saturn V Capital Management, EVENTIDE ASSET MANAGEMENT, based on the most recent SEC filings. IMMX trades on the Nasdaq exchange and files with the SEC under CIK 1873835. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMMX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immix Biopharma, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-11.6M
Free Cash Flow
Q2 2026
$-11.8M
ROIC
Q2 2026
-21.8%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-36.2% YoYOperating Income
-32.1% YoYEPS (Diluted)
-17.1% YoYTotal Assets
+356.9% YoYOp. Cash Flow
-64.0% YoYFree Cash Flow
-56.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-29.4M -36.2% | $-21.6M -40.1% | $-15.4M -87.4% | $-8.2M +66.2% | $-24.4M -2024.3% | $-1.1M |
| Operating Income | $-30.0M -32.1% | $-22.7M -40.5% | $-16.1M -96.4% | $-8.2M -507.9% | $-1.4M -197.9% | $-453.9K |
| EPS (Diluted) | $-0.89 -17.1% | $-0.76 +14.6% | $-0.89 -50.8% | $-0.59 | — | — |
| Total Assets | $104.8M +356.9% | $22.9M +15.2% | $19.9M +33.7% | $14.9M -18.1% | $18.2M +3271.4% | $539.6K |
| Operating Cash Flow | $-23.9M -64.0% | $-14.6M -28.3% | $-11.4M -53.5% | $-7.4M -366.1% | $-1.6M -292.7% | $-404.7K |
| Free Cash Flow | $-24.7M -56.4% | $-15.8M -38.1% | $-11.4M | — | $-1.6M | — |
Get alerted when IMMX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Immix Biopharma, Inc. including:
Top Institutional Holders of IMMX
Jupiter Topco LLC
$100.8M9,783,192 shSaturn V Capital Management LP
$48.0M4,658,429 shEVENTIDE ASSET MANAGEMENT, LLC
$40.1M3,891,019 shSTATE STREET CORP
$30.9M2,996,935 shBlackRock, Inc.
$30.8M2,989,972 shDeep Track Capital, LP
$28.6M2,775,000 shVANGUARD CAPITAL MANAGEMENT LLC
$25.8M2,507,122 shOpaleye Management Inc.
$24.2M2,345,000 shMILLENNIUM MANAGEMENT LLC
$21.3M2,066,426 shUBS Group AG
$20.0M1,941,817 sh
| Fund | Value | Shares |
|---|---|---|
| Jupiter Topco LLC | $100.8M | 9,783,192 |
| Saturn V Capital Management LP | $48.0M | 4,658,429 |
| EVENTIDE ASSET MANAGEMENT, LLC | $40.1M | 3,891,019 |
| STATE STREET CORP | $30.9M | 2,996,935 |
| BlackRock, Inc. | $30.8M | 2,989,972 |
| Deep Track Capital, LP | $28.6M | 2,775,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $25.8M | 2,507,122 |
| Opaleye Management Inc. | $24.2M | 2,345,000 |
| MILLENNIUM MANAGEMENT LLC | $21.3M | 2,066,426 |
| UBS Group AG | $20.0M | 1,941,817 |
More Healthcare Companies
View all Healthcare →Put IMMX on your watchlist
Track score changes the day Immix Biopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is IMMX a good stock to buy?
13F Pro's AI-powered analysis of Immix Biopharma, Inc. (IMMX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IMMX are available on the IMMX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IMMX is classified as a small company.
Which hedge funds own IMMX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IMMX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Immix Biopharma, Inc.'s investment landscape.